MBX Biosciences(MBX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MBX MBX Biosciences

Trading 08-26 15:09:03 EDT

67.21

-1.41

-2.05%

High68.83	Low66.27	Vol106.03K
Open68.56	D1 Closing68.62	Amplitude3.73%
Mkt Cap3.24B	Tradable Cap1.86B	Total Shares48.16M
T/O7.10M	T/O Rate0.38%	Tradable Shares27.63M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MBX","market":"US","secType":"STK","nameCN":"MBX Biosciences","latestPrice":67.21,"timestamp":1787771343533,"preClose":68.62,"halted":0,"volume":106031,"delay":0,"changeRate":-0.020547945205479607,"floatShares":27629899,"shares":48160096,"eps":-2.4052,"marketStatus":"Trading","change":-1.41,"latestTime":"08-26 15:09:03 EDT","open":68.56,"high":68.83,"low":66.27,"amount":7102935.046130001,"amplitude":0.037307,"askPrice":67.31,"askSize":172,"bidPrice":67.17,"bidSize":8,"shortable":3,"etf":0,"ttmEps":-2.4052,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787774400000},"marketStatusCode":2,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":68.62,"preHourTrading":{"tag":"盘前","latestPrice":68.41,"preClose":68.62,"latestTime":"08:49 EDT","volume":953,"amount":65292.39344,"timestamp":1787748587232,"change":-0.21,"changeRate":-0.00306,"amplitude":0.051006},"postHourTrading":{"tag":"盘后","latestPrice":68.62,"preClose":68.62,"latestTime":"19:30 EDT","volume":3818,"amount":261987.716,"timestamp":1787700602800,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.269484,"impliedVol":0.6442,"impliedVolPercentile":0.012},"requestUrl":"/m/hq/s/MBX/","defaultTab":"news","newsList":[{"id":"2661924292","title":"MBX Biosciences Price Target Announced at $88.00/Share by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2661924292","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661924292?lang=en_us&edition=fundamental","pubTime":"2026-08-22 03:12","pubTimestamp":1787339520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MBX/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661250734","title":"U.S. Research Roundup-Health Catalyst, Nektar Therapeutics, TIC Solutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2661250734","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661250734?lang=en_us&edition=fundamental","pubTime":"2026-08-21 15:26","pubTimestamp":1787297213,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Health Catalyst, Nektar Therapeutics, TIC SolutionsAug 21 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, incl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nL8N44I09H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COTY","IXN","TRFK","AVGO","ECG","LMB","ADSK","BAI","MTSI","BWMN","INNV","FTH","HCAT","BCAL","LEGR","AVGU","FERG","SMHX","MU","DISK","ACEL","AMP","EGGY","APP","VEGI","ADI","IMA","MATW","GTLB","FIX","DV","EBS","DE","P","AMYY","HL","MRVL","DOCS","FTAI","CHAT","MCHP","AMD","PI","AAP","HRZN","ABT","CTEV","LYTS","QBTS","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659122699","title":"13D Filings","url":"https://stock-news.laohu8.com/highlight/detail?id=2659122699","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659122699?lang=en_us&edition=fundamental","pubTime":"2026-08-15 07:06","pubTimestamp":1786748760,"startTime":"0","endTime":"0","summary":"These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GTE","BK4116","BK4215","MBX","UMH","BK4211","BK4608","CORZ","STCE","BK4082","BK4007","BK4228","BK4213","SI","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658398734","title":"Truist Adjusts Price Target on MBX Biosciences to $88 From $70, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2658398734","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658398734?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:11","pubTimestamp":1786356711,"startTime":"0","endTime":"0","summary":"MBX Biosciences (MBX) has an average rating of buy and mean price target of $88.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657362993","title":"MBX Biosciences, Inc. (MBX) Gets a Buy from Mizuho Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2657362993","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657362993?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:55","pubTimestamp":1786136131,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Uy Ear reiterated a Buy rating on MBX Biosciences, Inc. today and set a price target of $91.00. According to TipRanks, Ea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mbx-biosciences-inc-mbx-gets-a-buy-from-mizuho-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mbx-biosciences-inc-mbx-gets-a-buy-from-mizuho-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSIB","BK4007","MBX","BK4207","MFG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657612918","title":"MBX Biosciences price target raised to $88 from $70 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2657612918","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657612918?lang=en_us&edition=fundamental","pubTime":"2026-08-07 18:21","pubTimestamp":1786098101,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on MBX Biosciences (MBX) to $88 from $70 and keeps an Overweight rating on the shares. The firm updated the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mbx-biosciences-price-target-raised-to-88-from-70-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mbx-biosciences-price-target-raised-to-88-from-70-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656758","title":"Analysts Offer Insights on NA Companies: BillionToOne, Inc. Class A (BLLN) and MBX Biosciences, Inc. (MBX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656758","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657656758?lang=en_us&edition=fundamental","pubTime":"2026-08-07 00:50","pubTimestamp":1786035024,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on BillionToOne, Inc. Class A (BLLN) and MBX Biosciences, Inc. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-billiontoone-inc-class-a-blln-and-mbx-biosciences-inc-mbx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-billiontoone-inc-class-a-blln-and-mbx-biosciences-inc-mbx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007","BK4141","BK4196","BLLN","NA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657180658","title":"MBX Biosciences Shares Lower After Q2 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2657180658","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657180658?lang=en_us&edition=fundamental","pubTime":"2026-08-06 22:40","pubTimestamp":1786027259,"startTime":"0","endTime":"0","summary":"MBX Biosciences  shares were about 1.0% lower in Thursday trading following its Q2 results.Earlier, the clinical-stage biopharmaceutical company reported a Q2 net loss of $0.78 per share, compared with a loss of $0.58 a year ago.Looking ahead, the firm said its cash and investments are expected to support operations into 2029.Price: 66.78, Change: -0.70, Percent Change: -1.04","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657541637","title":"MBX Biosciences, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657541637","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657541637?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:47","pubTimestamp":1786024062,"startTime":"0","endTime":"0","summary":"MBX Biosciences, Inc. reports results for the quarter ended June 30 - Earnings SummaryMBX Biosciences, Inc.MBX.OQreported a quarterly adjusted loss of 78 cents per share for the quarter ended June 30,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N443229:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657118631","title":"MBX Biosciences Advances Canvuparatide and Obesity Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2657118631","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657118631?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:41","pubTimestamp":1786020108,"startTime":"0","endTime":"0","summary":"An announcement from MBX Biosciences, Inc. ( ($MBX) ) is now available. MBX Biosciences reported its second-quarter 2026 results on August 6, 2026,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mbx-biosciences-advances-canvuparatide-and-obesity-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mbx-biosciences-advances-canvuparatide-and-obesity-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657063991","title":"Earnings Flash (MBX) MBX Biosciences Posts Q2 Net Loss $0.78 a Share, vs. FactSet Est of $0.63 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657063991","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657063991?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:12","pubTimestamp":1786018336,"startTime":"0","endTime":"0","summary":"Earnings Flash (MBX) MBX Biosciences Posts Q2 Net Loss $0.78 a Share, vs. FactSet Est of $0.63 Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657639558","title":"MBX Biosciences Posts Corporate Presentation on Precision Peptide Programs for Endocrine, Metabolic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2657639558","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657639558?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:11","pubTimestamp":1786018268,"startTime":"0","endTime":"0","summary":"MBX Biosciences posts corporate presentation on precision peptide programs for endocrine, metabolic diseasesMBX Biosciences outlined a catalyst schedule led by canvuparatide (MBX 2109) Phase 3 initiat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL7Xfsrm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657563989","title":"MBX Biosciences Q2 FY26 Net Loss Widens to $37.1 Million; R&D Expenses Rise to $31 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657563989","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657563989?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:08","pubTimestamp":1786018099,"startTime":"0","endTime":"0","summary":"MBX Biosciences Q2 FY26 net loss widens to $37.1 million; R&D expenses rise to $31 millionMBX Biosciences posted a Q2 net loss of USD 37.1 million, widening from USD 19.4 million a year earlier.R&D ex","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL3ctvVZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657363621","title":"MBX Biosciences Q2 EPS $(0.78) Misses $(0.63) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657363621","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657363621?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:05","pubTimestamp":1786017924,"startTime":"0","endTime":"0","summary":"MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.63) by 23.81 percent. This is a 34.48 percent decrease over losses of $(0.58) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60991490/mbx-biosciences-q2-eps-0-78-misses-0-63-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657163674","title":"Press Release: MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2657163674","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657163674?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017600,"startTime":"0","endTime":"0","summary":"Results demonstrated sustained benefit of once-weekly canvuparatide as a. potential PTH replacement therapy through one year, with findings. consistent with restoration of systemic PTH activity through. normalization of serum calcium, reduction of urine calcium excretion and. restoration of bone metabolism, as well as a safety profile and. -- Phase 3 trial of once-weekly canvuparatide now recruiting: MBX remains on. track to initiate a Phase 3 pivotal trial of once-weekly canvuparatide in. chronic hypoparathyroidism in Q3 2026. Clinical trial sites have been. activated, and participants are currently being recruited and screened.The oPTimize Phase 3 pivotal, global, multicenter, randomized,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","HP","JDOC","BK4555","MBX","BK4604","03160","TM","BK4092","BK4585","BK4099","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655836604","title":"Mizuho Securities Sticks to Its Buy Rating for MBX Biosciences, Inc. (MBX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2655836604","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655836604?lang=en_us&edition=fundamental","pubTime":"2026-07-29 06:35","pubTimestamp":1785278120,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Uy Ear reiterated a Buy rating on MBX Biosciences, Inc. today and set a price target of $91.00. Ear covers the Healthcare...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-its-buy-rating-for-mbx-biosciences-inc-mbx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-its-buy-rating-for-mbx-biosciences-inc-mbx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653725753","title":"MBX Biosciences price target raised to $90 from $60 at UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2653725753","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653725753?lang=en_us&edition=fundamental","pubTime":"2026-07-23 21:41","pubTimestamp":1784814081,"startTime":"0","endTime":"0","summary":"UBS analyst Michael Yee raised the firm’s price target on MBX Biosciences (MBX) to $90 from $60 and keeps a Buy rating on the shares. The firm rema...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mbx-biosciences-price-target-raised-to-90-from-60-at-ubs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mbx-biosciences-price-target-raised-to-90-from-60-at-ubs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRTO","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652280598","title":"Is MBX Biosciences (MBX) Fairly Valued As New Leadership Takes Charge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2652280598","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652280598?lang=en_us&edition=fundamental","pubTime":"2026-07-18 03:23","pubTimestamp":1784316188,"startTime":"0","endTime":"0","summary":"Why this leadership shake up at MBX Biosciences matters for investors\nMBX Biosciences (MBX) is in focus after the board promoted Executive Chairman Steve Hoerter to Chief Executive Officer and Chairman, while confirming John Smither as Chief Financial Officer, reshaping the company’s senior leadership team.\nSee our latest analysis for MBX Biosciences.\nThe leadership changes at MBX Biosciences arrive after a sharp run up in momentum, with the stock showing a 45.47% 1 month share price return...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/news/is-mbx-biosciences-mbx-fairly-valued-as-new-leadership-takes","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/news/is-mbx-biosciences-mbx-fairly-valued-as-new-leadership-takes","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651441877","title":"MBX: Leadership Transition, Pipeline Visibility Support Maintained Buy Rating and Unchanged $91 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2651441877","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651441877?lang=en_us&edition=fundamental","pubTime":"2026-07-16 19:55","pubTimestamp":1784202923,"startTime":"0","endTime":"0","summary":"Analyst Patrick Dolezal of LifeSci Capital maintained a Buy rating on MBX Biosciences, Inc., retaining the price target of $91.00. Patrick Dolezal ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/mbx-leadership-transition-pipeline-visibility-support-maintained-buy-rating-and-unchanged-91-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/mbx-leadership-transition-pipeline-visibility-support-maintained-buy-rating-and-unchanged-91-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651493986","title":"Analysts’ Top NA Picks: SanDisk Corp (SNDK), MBX Biosciences, Inc. (MBX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651493986","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651493986?lang=en_us&edition=fundamental","pubTime":"2026-07-16 03:20","pubTimestamp":1784143210,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 3 analysts just weighed in on SanDisk Corp (SNDK), MBX Biosciences, Inc. (MBX) and Kestra ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-na-picks-sandisk-corp-sndk-mbx-biosciences-inc-mbx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-na-picks-sandisk-corp-sndk-mbx-biosciences-inc-mbx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861215975.USD","LU2360107168.USD","TMSL","LU2543165471.USD","BK4007","MBX","PTF","SCHM","SNDG","SNDQ","LU2290526834.HKD","SNDK","SNDU","LU0963586101.USD","LU2063271972.USD","CNAV","SCHA","OPTZ","SNXX","FCUS","BK4170","COWG","LU0054578231.USD","SNDC","QQQG","LU1861220033.SGD","FSMD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mbxbio.com","stockEarnings":[{"period":"1week","weight":0.0316},{"period":"1month","weight":0.1068},{"period":"3month","weight":1.1524},{"period":"6month","weight":0.9583},{"period":"1year","weight":3.9402},{"period":"ytd","weight":1.1756}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0365},{"period":"3month","weight":0.0206},{"period":"6month","weight":0.1111},{"period":"1year","weight":0.1921},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MBX Biosciences, Inc. was incorporated in August 2018 as an Indiana limited liability company and converted to a Delaware corporation in April 2019. The company is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision peptide therapeutics for endocrine and metabolic disorders. Its pipeline includes drug candidates for hypoparathyroidism, obesity, and post-bariatric hypoglycemia, designed using its proprietary Precision Endocrine Peptide (PEP) platform.","exchange":"NASDAQ","name":"MBX Biosciences","nameEN":"MBX Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MBX Biosciences(MBX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MBX Biosciences(MBX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MBX Biosciences,MBX,MBX Biosciences股票,MBX Biosciences股票老虎,MBX Biosciences股票老虎国际,MBX Biosciences行情,MBX Biosciences股票行情,MBX Biosciences股价,MBX Biosciences股市,MBX Biosciences股票价格,MBX Biosciences股票交易,MBX Biosciences股票购买,MBX Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MBX Biosciences(MBX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MBX Biosciences(MBX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}